Die Mehrwertsteuer, insbesondere im Pharma Bereich für Konzerne, KMUs und Start-ups, ist im steten Wandel und immer transparenter.
Für Sie als Entscheidungsträger im Pharma & Life Sciences Bereich, wird es immer schwieriger all die gesetzlichen und behördlichen Vorgaben / Neuerungen effizient und kostengünstig einzuhalten. Dazu kommt die aktuelle COVID-19 Situation, welche umsatzsteuerliche Herausforderungen mit sich bringt und die es zu meistern gilt. Gleichzeitig spielt Industrie 4.0, die umfassende Digitalisierung der industriellen Produktion, die den absehbaren Wandel herbeiführt, aber auch neue Chancen zur Prozessoptimierung bietet, eine immer wichtigere Rolle.
Continue reading PwC Event – 5. Schweizer MWST-Tagung – 05. November 2020, Bellevue Palace Bern
Discover PwC’s four cutting edge digital tax & regulatory solutions and how they can add value to your business, help you complying with new laws, stay up to date with upcoming changes in legislation and regulatory.
Continue reading Pharma & Life Sciences: 4 cutting edge digital tax & regulatory solutions
Dear pharma & life sciences colleagues,
It was a pleasure to welcome you to our webinar: PwC Pharma & Life Sciences Webinar: COVID-19 impact on the ITX and regulatory DNA.
Attached below you can download the presentation.
Continue reading PwC Pharma & Life Sciences Webinar: COVID-19 impact on the ITX and regulatory DNA
As the COVID-19 situation develops, tax and regulatory specialists within the pharmaceutical & life sciences industry are increasingly facing complex challenges. Efficient and pragmatic solutions have to be realised, with fewer resources, in line with the changing local legislation.
The exchange of information is the best practice in this industry to support and inspire you in your daily business.
Continue reading PwC Pharma & Life Sciences Webinar: COVID-19 impact on the ITX and regulatory DNA – Thursday 28. May 2020, 10:30 CEST
Animal nutrition company BIOMIN America was fined by more than $250’000 for coordinating sales of agricultural commodities to a company in Cuba without authorization from OFAC (US Office of Foreign Assets Controls).
Continue reading OFAC fined US subsidiary of Austrian ERBER Group after misinterpreting US Sanctions
As an effort to limit the impact of COVID-19, the Belgian government has introduced a temporary relief measure whereby certain goods imported into Belgium can benefit from a VAT and duty exemption.
A key condition to benefit from said exemption entails the importation by a so-called recognized healthcare institution (almost all Belgian hospitals qualify as such an institution).
Continue reading Will you change your supply chain to benefit from a VAT and duty free importation into Belgium?
In one of our previous posts we draw your attention to the upcoming deadline of May 26th, 2020 which was the date on which the MDR, i.e. the new EU regulation concerning medical devices was expected to be fully applicable.
Continue reading Great news for Swiss Medtech companies – Postponement of the application date of MDR
I would like to invite you to our next
webinar “PwC webinar – “Sourcing and manufacturing without side
effects!” which will be held on 31 March 2020 from 3:00 pm to 4:00 pm and
on 1 April 2020 from 9.00 am to 10.00 am.
We will also include some ITX Updates
related on COVID-19.
Continue reading PwC webinar – “Sourcing and manufacturing without side effects!” / COVID-19 ITX Update
the economic impact is unknown scenario planning is key
The impact and effects of COVID-19 are
being felt by businesses globally, and particularly in China where necessary
radical measures to contain the outbreak are impacting day to day life.
Continue reading Succeeding in Uncertainty: Responding to COVID-19
Medical devices suppliers conducting agreements for allowing hospitals to use free of charge their equipment might face both VAT and corporate tax adverse implications.
Continue reading Cutting edge tax implications for medical devices suppliers in Europe